Promoter Methylation Status and and Expression in Patients With Wild-type KRAS Gene in Colorectal Cancer

Overview

Journal Cancer Diagn Progn

Specialty Oncology

Date 2022 Sep 5

PMID 36060016

Authors

Jehison Alirio Herrera-Pulido

Orlando Ricaurte Guerrero

Jinneth Acosta Forero

Pablo Moreno-Acosta

Alfredo Romero-Rojas

Carolina Sanabria

Gustavo Hernandez

Martha Lucia Serrano

Affiliations

Soon will be listed here.

Abstract

Background/aim: Although some mutations of KRAS proto-oncogene, GTPase (KRAS) have been associated with the prognosis and therapeutic management of colorectal cancer (CRC), the epigenetic mechanisms (DNA methylation and microRNA expression) that regulate wild-type KRAS expression in patients with CRC are poorly known. The aim of this study was to establish whether there is a relationship between the expression of the wild-type KRAS gene, the methylation status of its distal promoter, and miR-143 and miR-18a-3p levels in samples of sporadic CRC.

Patients And Methods: A total of 51 cases of sporadic CRC with wild-type KRAS were analyzed. The expression levels of KRAS mRNA, miR-18a-3p, miR-143, and KRAS protein, as well as methylation in the distal promoter of the KRAS gene were evaluated.

Results: In the analyzed cases, KRAS mRNA expression was detected in 51.1%; wild-type KRAS protein was found in the membrane in 31.4% and in the cytoplasm in 98% of cases. An inverse relationship of marginal significance was observed between miR-18a-3p and KRAS protein expression in the cytoplasm (odds ratio=0.14, 95% confidence interval=0.012-1.092; p=0.08). The methylation status of the distal promoter of KRAS at four CpG islands was analyzed in 30 cases (58.8%): partial methylation of the four CpG islands evaluated was observed in two cases (6.7%). In these cases, KRAS protein expression was not evidenced at the membrane level; miR-18a-3p expression was not detected either but high expression of miR-143 was observed.

Conclusion: No association was found between the expression levels of KRAS mRNA, miR-18a-3p, miR-143 and methylation status. Methylation status was detected with low frequency, thus being the first report of methylation in wild-type KRAS.

References

Ines C, Donia O, Rahma B, Ammar A, Sameh A, Khalfallah T . Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort. Tumour Biol. 2014; 35(7):7163-75. DOI: 10.1007/s13277-014-1874-4. View

Malhotra P, Anwar M, Nanda N, Kochhar R, Wig J, Vaiphei K . Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumour Biol. 2013; 34(3):1901-11. DOI: 10.1007/s13277-013-0734-y. View

Roost C, Lynch S, Batista P, Qu K, Chang H, Kool E . Structure and thermodynamics of N6-methyladenosine in RNA: a spring-loaded base modification. J Am Chem Soc. 2015; 137(5):2107-15. PMC: 4405242. DOI: 10.1021/ja513080v. View

Zhang Z, Wang Y, Vikis H, Johnson L, Liu G, Li J . Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet. 2001; 29(1):25-33. DOI: 10.1038/ng721. View

Jancik S, Drabek J, Radzioch D, Hajduch M . Clinical relevance of KRAS in human cancers. J Biomed Biotechnol. 2010; 2010:150960. PMC: 2896632. DOI: 10.1155/2010/150960. View

Jordano J, Perucho M . Initial characterization of a potential transcriptional enhancer for the human c-K-ras gene. Oncogene. 1988; 2(4):359-66. View

Fiala O, Sorejs O, Hosek P, Liska V, Vycital O, Bruha J . Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer. Cancer Genomics Proteomics. 2020; 17(5):605-613. PMC: 7472450. DOI: 10.21873/cgp.20217. View

Zhang C, Zhao H, Li J, Liu H, Wang F, Wei Y . The identification of specific methylation patterns across different cancers. PLoS One. 2015; 10(3):e0120361. PMC: 4361543. DOI: 10.1371/journal.pone.0120361. View

Luo F, Poulogiannis G, Ye H, Hamoudi R, Dong G, Zhang W . Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation. Int J Exp Pathol. 2013; 95(1):8-15. PMC: 3919644. DOI: 10.1111/iep.12064. View

10.

Schmick M, Vartak N, Papke B, Kovacevic M, Truxius D, Rossmannek L . KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport. Cell. 2014; 157(2):459-471. DOI: 10.1016/j.cell.2014.02.051. View

11.

Lv J, Liu H, Su J, Wu X, Liu H, Li B . DiseaseMeth: a human disease methylation database. Nucleic Acids Res. 2011; 40(Database issue):D1030-5. PMC: 3245164. DOI: 10.1093/nar/gkr1169. View

12.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

13.

Perl K, Ushakov K, Pozniak Y, Yizhar-Barnea O, Bhonker Y, Shivatzki S . Reduced changes in protein compared to mRNA levels across non-proliferating tissues. BMC Genomics. 2017; 18(1):305. PMC: 5395847. DOI: 10.1186/s12864-017-3683-9. View

14.

Akao Y, Nakagawa Y, Naoe T . MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep. 2006; 16(4):845-50. View

15.

Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M . Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010; 28(12):1248-50. DOI: 10.1038/nbt1210-1248. View

16.

Vaiopoulos A, Athanasoula K, Papavassiliou A . Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges. Biochim Biophys Acta. 2014; 1842(7):971-80. DOI: 10.1016/j.bbadis.2014.02.006. View

17.

Michael M, O Connor S, van Holst Pellekaan N, Young G, James R . Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003; 1(12):882-91. View

18.

Ng E, Tsang W, Ng S, Jin H, Yu J, Li J . MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer. 2009; 101(4):699-706. PMC: 2736825. DOI: 10.1038/sj.bjc.6605195. View

19.

Parrish R, Day J, Lubin F . Direct bisulfite sequencing for examination of DNA methylation with gene and nucleotide resolution from brain tissues. Curr Protoc Neurosci. 2012; Chapter 7:Unit 7.24. PMC: 3395468. DOI: 10.1002/0471142301.ns0724s60. View

20.

Cui S, Wang R, Chen L . MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med. 2014; 18(10):1913-26. PMC: 4244007. DOI: 10.1111/jcmm.12358. View